Vivani Medical (VANI) Emerging Growth Virtual Conference summary

Company overview and technology focus

• Develops miniature biopharmaceutical implants for steady, long-term drug delivery, initially targeting GLP-1 class medications for obesity and type 2 diabetes.

• Proprietary NanoPortal platform uses titanium oxide nanotube membranes for controlled, constant drug release.

• Lead programs include NPM-115 (exenatide implant for obesity, twice yearly dosing), NPM-139 (semaglutide implant, once yearly dosing), and NPM-119 (for type 2 diabetes).

• Pipeline includes animal health applications and potential for broader disease areas.

• Platform technology is protected by multiple patents, with coverage into the 2030s and 2040s.

Clinical and preclinical progress

• First clinical trial (LIBERATE-1) began at end of last year, rapidly enrolled 24 subjects across two sites.

• Study compares exenatide implant, Bydureon, and semaglutide, focusing on safety, tolerability, and pharmacokinetics over nine weeks.

• Positive preclinical data for NPM-139 (semaglutide implant) showed nearly 20% weight loss maintained over 91 days after a single administration.

• Animal studies demonstrated durable weight loss and reduced liver fat with exenatide implant.

• Top-line data from the first clinical study expected mid-year, with a dose-ranging study and potential registrational trial to follow.

Market opportunity and strategic direction

• GLP-1 class drugs are blockbuster treatments for obesity and diabetes, but real-world adherence and persistence are low, leading to suboptimal outcomes.

• Implants aim to address adherence and persistence by providing steady drug levels and reducing side effects.

• Patient research indicates strong interest in long-acting GLP-1 implants, especially among those already on GLP-1 therapy.

• Company is prioritizing obesity and weight management, with diabetes as a secondary focus.

• Financial runway extends into Q2 2026 following recent $8.25 million financing.